2023
Chen WC, Choudhury A, Youngblood MW, Polley MYC, Lucas CHG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci A, Harmanci A, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JKS, Li LF, Leung GKK, Chan JW, Perlow HK, Palmer JD, Haberler C, Bergoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young J, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Oberheim Bush NA, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023. PMID: 37944590.
Raleigh DR and Preusser M. A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses. Neuro-Oncol. 2023. PMID: 37963810.
Khan AB, English CW, Chen WC, Athukuri P, Bayley JC, Brandt VL, Shetty A, Hadley CC, Choudhury A, Lu HC, Harmanci AO, Harmanci AS, Magill ST, Raleigh DR, Klisch TJ, Patel AJ. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023. PMID: 36729132.
Krishna S, Choudhury A, Seo K, Ni L, Kakaizada S, Lee A, Aabedi A, Cao C, Sudharshan R, Egladyous A, Almeida N, Venkatesh H, Findlay A, Nagarajan S, Raleigh DR, Brang D, Monje M, Hervey-Jumper SL. Glioblastoma remodeling of neural circuits in the human brain decreases survival. Nature. 2023. PMID: 3713806.
Tang V, Lu R, Mirchia K, Van Ziffle J, Devine P, Lee J, Phillips J, Perry A, Raleigh DR, Lucas CHG, Solomon DA. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathol. 2023. PMID: 36723772.
Wang JZ, Patil V, Liu J, Dogan H, Tabatabi G, Yefet LS, Behling F, Hoffman E, Bunda S, Yakubov R, Kaloti R, Brandner S, Gao A, Cohen-Gaol A, Barnholtz-Soan J, Skardelly M, Tatagiba M, Raleigh DR, Sahm F, Boutros PC, Aldape K, Nassiri F, Zadeh G. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol. 2023. PMID: 37093270.
Perlow HK, Nalin AP, Handley D, Gokun Y, Blakaj DM, Beyer SJ, Thomas EM, Raval RR, Boulter D, Kleefisch C, Bovi J, Chen WC, Brausntein SE, Raleigh DR, Knisely JPS, Ivanidze J, Palmer JD. A prospective registry study of 68Ga-DOTATATE PET/CT incorporation into treatment planning of intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2023. PMID: 37871886.
2022
Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, Seo K, Lucas CHG, Casey-Clyde TJ, Vasudevan HN, Liu SJ, Villanueva-Meyer JE, Lam TC, Pu JKS, Li LF, Leung GKK, Swaney, DL, Zhang MY, Chan JW, Qiu Z, Martin MV, Susko MS, Braunstein SE, Oberheim Bush NA, Schulte J, Butowski N, Sneed PK, Berger MS, Krogan NJ, Perry A, Phillips JJ, Solomon DA, Costello JF, McDermott MW, Rich JN, Raleigh DR. Meningioma DNA methylation groups reveal biological drivers and therapeutic vulnerabilities. Nat Genet. 2022. 54:649-659. PMID 35534562. Link to meningioma DNA methylation classification application here.
Vasudevan HN, Choudhury A, Hilz S, Villaneuva-Meyer JE, Chen WC, Lucas CHG, Braunstein SE, Oberheim Bush NA, Butowski N, Pekmezci M, McDermott MW, Perry A, Colomon DA, Magill ST, Raleigh DR. Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathologica. PMID: 35759011.
Lo M, Sharir A, Paul MD, Torosyan H, Agnew C, Li A, Neben C, Marangoni P, Xu L, Raleigh DR, Jura N, Klein OD. CNPY4 inhibits the Hedgehog pathway by modulating membrane sterol levels. Nat Commun. 2022. 13:2407. PMID: 35504891.
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury G, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alecander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi WL. A molecularly integrated grade for meningioma. Neuro Oncol. 2022. PMID: 34508644.
Peng KL, Vasudevan HN, Lockney DT, Baum R, Hendrickson RC, Raleigh DR‡, Schmitt AM‡. LncRNA Miat and metadherin maintain a treatment resistant stem-cell niche of medulloblastoma cells. Proc Nat Acad Sci. 2022. PMID: 36067288.
Choudhury A, Chen WC, Lucas CHG, Bayley JC, Harmanci AS, Maas SLN, Santagata S, Klisch T, Perry A, Bi WL, Sahm F, Patel A, Magill, ST, Raleigh DR. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro-Oncol. 2022. PMID: 36227281.
Chen WC, Perlow HK, Choudhury A, Nguyen MP, Mirchia K, Youngblood MW, Lucas CHG, Palmer JD, Magill ST, Raleigh DR. Radiotherapy for meningiomas. J Neurooncol. 2022. PMID: 36227281.
Lee D, Gimple RC, Prager BC, Qiu Z, Wu Q, Daggubati V, Daggubati V, Gopalakrishnan J, Sarkisian MR, Raleigh DR†, Rich JF†. Superenhancer-activation of KLHDC8A drives glioma ciliation and Hedgehog signaling. J Clin Invest. 2022. PMID: 36394953.
Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, Gupta N, Rosi S, Chang S, Raleigh DR, Solomon DA, Phillips JJ, Diaz AA. A single-cell atlas of glioblastoma evolution under therapy. Nat Cancer. 2022. PMID: 36539501.
Prasad RN, Perlow HK, Bovi J, Braunstein SE, Ivanidze J, Kalapurakal JA, Kleefisch C, Knisely JPS, Mehta MP, Prevedello DM, Raleigh DR, Mishra MB, Roberge D, Rogers CL, Palmer JD. 68Ga-DOTATATE PET: The future of meningioma treatment. Int J Radiat Oncol Biol Phys. 2022. PMID: 35772444.
Nguyen MP, Seo Kyounghee, Eaton CD, Lucas CHG, Chen WC, Choudhury A, Young JS, Raleigh DR. A case (report) for mechanistic validation of meningioma molecular therapies. Neuro-Oncol Advanc. 2022. PMID: 36382111.
2021
Findakly S, Daggubati V, Garcia G, LaStella S, Choudhury A, Tran C, Li A, Tong P, Garcia JQ, Puri N, Reiter JF, Xu L, Raleigh DR. Sterol and oxysterol syntheses near the ciliary base activate the Hedgehog pathway. J Cell Biol. 2021. 220:e202002026. PMID: 33284321.
Vasudevan HN. Lucas CHG, Villanueva-Meyer JE, Theodosopoulos PV, Raleigh DR. Genetic events and signaling mechanisms underlying Schwann cell fate in development and cancer. Neurosurg. 2021. 88:234-245. PMID: 33094349.
Susko MS, Chen WC, Vasudevan HN, Magill ST, Lucas CHG, Oberheim Bush NA, Solomon DA, Theodosopoulos OV, McDermott MW, Villanueva-Meyer JE, VOreta L, Nakamura JL, Sneed PK, Braunstein SE, Raleigh DR. Letter: Patterns of intermediate and high-risk meningioma recurrence after treatment with postoperative external beam radiotherapy. Neurosurg. 2021. PMID: 33887769.
Daggubati V, Hochstelter J, Bommireddy A, Choudhury A, Krup AL, Kaur P, Tong P, Li A, Libin X, Reiter JF, Raleigh DR. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models. J Clin Invest. 2021. 2020:e202002026. PMID: 33476305.
Chen WC, Baal UH, Baal JD, Pai JS, Boreta L, Braunstein SE, Raleigh DR. Efficacy and safety of stereotactic radiosurgery for brainstem metastases: a systematic review and meta-analysis. JAMA Oncology. 2021. PMID: 33983393.
Daggubati V, Raleigh DR, Sever N. Sterol regulation of developmental and oncogenic Hedgehog signaling. Biochem pharmacol. 2021. PMID: 34111427.
Oberheim Bush NA, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol. 2021. PMID: 34125374.
Ni L, Thomas HR, Raleigh DR, Boreta LC, Park CC, Braunstein SE. Residents-as-teachers curriculum for radiation oncology: a targeted needs assessment. Int J Radiat Oncol Biol Phys. 2021. PMID 34153380.
2020
Susko MS, Garcia MA, Ma L, Nakamura JL, Raleigh DR, Fogh S, Theodosopoulos P, McDermott MW, Sneed PK, Braunstein SE. Stereotactic radiosurgery to greater than 10 brain metastases: Evidence to support the role of radiosurgery for ideal hippocampal sparing in the treatment of multiple brain metastases. World Neurosurg. 2020. 135:e174-e180. PMID: 31785436.
Choudhury A, Neumann N, Raleigh DR, Lang UE. Clinical implications of primary cilia in skin cancer. Derm Ther. 2020. 10:233-248. PMID: 31785436.
Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, Braunstein SE, Raleigh DR. Stereotactic body radiotherapy for adrenal gland metastases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients. Int J Rad Oncol Bio Phys. 2020. 107:48-61. PMID: 32001383.
Bhaduri A, Di Lullo E, Jung D, Muller S, Crouch EE, Espinosa CS, Ozawa T, Alvarado B, Spatazza J, Cadwell CR, Wilkins G, Velmeshev D, Liu SJ, Malatesta M, Andrews MG, Mostajo-Radji MA, Huang EJ, Nowakowski TJ, Lim DA, Diaz A, Raleigh DR‡, Kriegstein AR‡. Outer radial glial-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell. 2020. 26:48-63. PMID: 31901251.
Liu SJ, Magill ST, Vasudevan HN, Hilz S, Villanueva-Meyer JE, Lastella S, Daggubati V, Spatz J, Choudhury A, Orr BA, Seo K, Ferris SP, Oberheim Bush NA, Bollen AW, McDermott MW, Costello JF, Raleigh DR. Multiplatform molecular profiling reveals epigenomic intratumor heterogeneity in ependymoma. Cell Reports. 2020. 30:1300-1309. PMID: 32023450.
Vasudevan HN, Castro MRH, Lee J, Villanueva-Meyer JE, Oberheim Bush NA, McDermott MW, Solomon DA, Perry A, Magill ST. Raleigh DR. DNA methylation profiling demonstrates superior diagnostic classification to RNA-sequencing in a case of metastatic meningioma. Acta Neuropathol Commun. 2020. 8:82. PMID 32517746.
Liu SJ, Malatesta M, Lien BV, Saha P, Thombare SS, Hong SJ, Pedraza L, Koontz M, Seo K, Horlbeck MA, He D, Birk HS, Jain M, Olsen HE, Akeson M, Weissman JS, Monje M, Gupta N, Raleigh DR, Ullian E, Lim DA. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020. 21:83. PMID: 32234056.
Chen WC, Vasudevan HN, Choudhury A, Pekmezci M, Lucas CH, Phillips J, Magill ST, Susko MS, Braunstein SE, Oberheim Bush NA, Boreta L, Nakamura JL, Villanueva-Meyer JE, Sneed PK, Perry A, McDermott MW, Solomon DA, Theodosopoulos PV, Raleigh DR. A prognostic gene expression signature and risk score for meningioma recurrence after resection. Neurosurg. 2020. ePub ahead of print. PMID 32860417.
Findakly S, Choudhury A, Daggubati V, Pekmezci M, Lang UE, Raleigh DR. Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals. Acta Neuropathol Commun. 2020. 8:114. PMID 32690089.
Prager B, Vasudeva HN, Dixit D, Bernatchez J, Wu Q, Spanlger L, Bhargava S, Lee D, King B, Morton A, Gimple R, Siqueira-Neto J, Wang X, Xie Q, Barnett G, Vogelbaum M, Mack S, Chavez L, Perry A, Raleigh DR‡, Rich J‡. The meningioma enhancer landscape delineates prognostic subgroups and drives druggable dependencies. Cancer Discovery. 2020. ePub ahead of print. PMID 32703768.
Haddad AF, Young JS, Kanugo I, Sudhir S, Chen JS, Magill ST, Raleigh DR, McDermott MW, Aghi MK. WHO grade I meningioma recurrence: identifying high risk patients using histopathological features and the MIB-1 index. Front Oncol. 2020. 28:1522. PMID 32983999.
Magill ST, Vasudevan HN, Seo K, Villanueva-Meyer JE, Choudhury A, Liu SJ, Pekmezci M, Findakly S, Hilz S, LaStella S, Demaree B, Braunstein SE, Oberheim Bush NA, Aghi M, Theodosopoulos PV, Sneed K, Abate AR, Berger MS, McDermott MW, Lim DA, Ullian EM, Costello JF, Raleigh DR. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Comms. 2020. 11:4803. PMID: 32968068.
Lucas CHG, Vasudevan HN, Chen WC, Magill ST, Braunstein SE, Jacques L, Dahiya S, Rodriguez FJ, Horvai AE, Perry A, Pekmezci M, Raleigh DR. Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival. Neurooncol Adv. 2020. 1:vdz131. PMID: 33880447.
2019
Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR. Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology. 2019. 21:18-31. PMID: 30649489.
Raleigh DR, Reiter JF. Misactivation of Hedgehog signaling causes inherited and sporadic cancers. J Clin Invest. 2019. 129:465-475. PMID: 30707108.
Baal JD, Chen WC, Solomon DA, Pai JS, Lucas CH, Hara JR, Oberheim Bush NA, McDermott MW, Raleigh DR†, Villanueva-Meyer JE†. Preoperative MR imaging to differentiate chordoid meningiomas from other meningiomas. AJNR Am J Neuroradiol. 2019. 40:433-439. PMID: 30819773.
Fritchie K, Jensch K, Moskalev EA, Caron A, Jenkins A, Link M, Brown P, Rodriguez F, Guajardo A, Brat D, Velazquez Vega JE, Perry A, Wu A, Raleigh DR, Santagata S, Louis D, Brastianos P, Kaplan A, Alexander B, Rossi S, Ferrarese F, Haller F, Giannini C. The impact of histopathology and NAB2-STAT6 fusion in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol. 2019. 137:207-219. PMID: 3054643.
Magill ST, Shahin MN, Lucas C, Yen AJ, Lee DS, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW. Surgical outcomes, complications and management strategies for foramen magnum meningiomas. J Neurol Surg B Skull Base. 2019. 80:1-9. PMID: 30733894.
Lee JC, Mazor T, Lao R, Wan E, Diallo A, Hill N, Thangaraj N, Wendelsdorf K, Samuel D, Kline C, Banerjee A, Auguste K, Raffel C, Gupta N, Berger MS, Raleigh DR, Shai A, Phillips J, Bollen AW, Tihan T, Perry A, Costello J, Solomon DA. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropatholog. 2019. 137:851-854. PMID: 30877433.
Voce D, Bernal G, Wu L, Crawley C, Zhang W, Mansour N, Cahill K, Uppal A, Raleigh DR, Spretz R, Nunez L, Larsen G, Khodarev N, Weichselbaum R, Yamini B. Temozolomide treatment induces lncRNA MALAT1 in and NF-kB and p53 co-dependent manner in glioblastoma. Cancer Research. 2019. 79:2536-2548. PMID: 30940658.
Dalle Ore CL, Magill ST, Yen AJ, Shahin MN, Lee DS, Lucas CHG, Chen WC, Viner JA, Aghi MK, Theodosopoulos PV, Raleigh DR, Villanueva-Meyer JE, McDermott MW. Meningioma metastases: incidence and proposed screening paradigm. J Neurosurg. 2019. 5:1-9. PMID: 30952122.
Morin O, Chen WC, Magill ST, Wu A, Gennatas ED, Vallieres M, Valdes G, Pekmezci M, Choudhury A, Interian Y, Mortezavi S, Turgutlu K, Oberheim Bush NA, Solberg TD, Braunstein SE, Sneed PK, Perry A, McDermott MW, Villanueva-Meyer JE, Raleigh DR. Integrated prognostic models incorporating preoperative radiologic and radiomic features identify meningioma grade, local failure and overall survival. Neurooncol Adv. 2019. 1:vdz011. PMID: PMC6777505.
Streckert EMS, Hess K, Sporns PB, Adeli A, Brokinkel C, Kriz J, Holling M, Eich HT, Paulus W, Spille DC, van Eck ATCJ, Raleigh DR, McDermott MW, Stummer W, Brokinkel B. Clinical, radiological and histopathological predictors for long-term prognosis after surgery for atypical meningiomas. Acta Neurochir. 2019. 161:1647-1656. PMID: 31147831.
Susko M, Yu Y, Ma L, Nakamura J, Fogh S, Raleigh DR, Golden E, Theodosopoulos PV, McDermott MW, Sneed PK, Braunstein SE. Pre-operative dural contact and recurrence risk after surgical cavity stereotactic radiosurgery for brain metastases: new evidence in support of consensus guidelines. Adv Radiat Oncol. 2019. 14:458-465. PMID: 31360800.
Wang S, Blaha C, Santos R, Huynh T, Hayes T, Beckford Vera DR, Blecha J, Hong A, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. Synthesis and inhiation biological evaluation of borane-containing prostate specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy. Mol Pharm. 2019. 16:3831-3841. PMID: 31381351.
Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke J, Torkildson J, Kline C, Alyssa R, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni P, Chou D, Tan L, Theodosopoulos P, Berger M, Raffel C, Gupta N, Sun P, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Gup H, Moes G, Kim J, Koschmann, C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee J, Pekmezci M, Phillips J, Tihan T, Bollen AW, Perry A, Solomon DA. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019. 138:877-881. PMID: 31515627.
Chapman CH, Hara JH, Molinary AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SW, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. Reirradiation of recurrent high grade glioma: outcomes and prognostic scores. Neuro-Oncology Practice. 2019. 138:877-881. PMID: 31515627.
2018
Vasudevan HN, Braunstein SE, Phillips JJ, Tomlin BA, Pekmezci M, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Reports. 2018. 22:3672-3683. PMID: 29590631.
Chen WC, Magill ST, Wu A, Vasudevan HN, Morin O, Aghi MK, Theodosopoulos PV, Perry A, McDermott, MW, Sneed PK, Braunstein SE, Raleigh DR. Histopathologic features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J Neurosurg. 2018. 130:443-450. PMID: 29624151.
Magill ST, Lee DS, Yen AJ, Lucas CHG, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW. Surgical outcomes after reoperation for recurrent skull base meningiomas. J Neurosurg. 2018. 130:876-883. PMID: 29726777.
Magill ST, Rick JW, Chen WC, Haase D, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW. Petrous face meningiomas: Classification, clinical syndromes, management and surgical outcomes. World Neurosurg. 2018. 114:e1266-e1274. PMID: 29626689.
Chen WC, Hara J, Magill ST, Wu A, Aghi MK, Theodosopoulos, PV, Perry A, McDermott MW, Sneed PK, Raleigh DR†, Braunstein SE†. Salvage therapy outcomes for atypical meningioma. J Neuro Oncol. 2018. 138:425-433. PMID: 29480505.
Deist TM, Dankers FJWM, Valdes G, Wijsman R, Hsu I, Oberije C, Lustber T, van Soest J, Hoebers F, Jochems A, El Nawa I, Wee L, Morin O, Raleigh DR, Bots W, Kaanders JH, Belderbos J, Kwint M, Solber T, Monshouwer R, Bussink J, Dekker A, Lambin P. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: an empirical comparison of classifiers. Med Phys. 2018. 45:3449-3459. PMID: 29763967.
Han DY, Braunstein SE, Raleigh DR, Sneed PK, McDermott MW, Ma L. Resection cavity contraction effects in use of radioactive sources (I-125 versus Cs-131) for intra-operative brain implants. Cereus. 2018. 10:e2079. PMID: 29560292.
Garcia G, Raleigh DR, Reiter JR. Organizing inside-out to communicate outside-in: how the ciliary membrane is specialized for signaling. Curr Biol. 2018. 23:R421-R434. PMID: 29689227.
Raleigh DR, Sever N, Choksi PK, Sigg MA, Hines KM, Thompson BM, Elnatan D, Jaishankar P, Bisignano P, Bisignano P, Garcia-Gonzalo FR, Eamon B, Choksi S, Krup AL, Eberl M, Wong SY, Renslo A, Siebold C, Grabe M, McDonald JG, Xu L, Beachy PH, Reiter JF. Cilia-associated oxysterols activate Smoothened. Mol Cell. 2018. 72:316-327. PMID: 30340023.
Gennatas ED, Wu A, Braunstein SE, Morin O, Chen WC, Magill ST, Villanueva-Meyer JE, Solberg TD, Valdes G, Raleigh DR. Preoperative and postoperative prediction of long-term meningioma outcomes. PLOS One.2018. 13:e0204161. PMID: 30235308.
Hara JH, Morin O, Wu A, Villanueva-Meyer J, Valdes G, Mueller S, Solberg T, Braunstein SE, Raleigh DR.Clinical applications of three-dimensional MRI analysis for pediatric embryonal brain tumors. Int J Rad Oncol Bio Phys. 2018. 102:744-756. PMID: 30108003.
Magill ST, Dalle Ore CL, Diaz MA, Jalil DD, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW. Surgical outcomes after reoperation for recurrent non-skull base meningiomas. J Neurosurg. 2018. 1:1-9. PMID: 30544357.
2017
Magill ST, Lau D, Raleigh DR, Sneed PK, McDermott MW. Surgical resection and interstitial 125I brachytherapy for high grade meningioma: a 25-year series. Neurosurg. 2017. 80:409-416. PMID: 27258768.
Raleigh DR†, Solomon DA†, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017. 19:78-88. PMID: 27282397.
Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess C, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott MW, Sneed PK, Braunstein SE. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes. J Neurosurg. 2017. 126:1756-1763. PMID: 27367235.
Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. Resection and brain brachytherapy with permanent iodine-125 seeds for brain metastasis. J Neurosurg. 2017. 126:1749-1755. PMID: 27367240.
Raleigh DR, Tomlin B, Del Buono B, Roddy E, Sear K, Byer L, Felton E, Banerjee A, Torkildson J, Samuel D, Horn B, Braunstein SE, Haas-Kogan DA, Mueller S. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. J Neurooncol. 2017. 131:359-368. PMID: 27778212.
Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein SE, Torkildson J, Samuel D, de Alba Campomanes A, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn M, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric brain tumor patients improves diagnosis, identified pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017. 19:699-709. PMID: 27978508.
Braunstein SE†, Raleigh DR†, Bindra R, Mueller S, Haas-Kogan DA. Pediatric high grade gliomas. J Neurooncol. 2017. 124:541-549. PMID: 28357536.
Vasudevan HN†, Raleigh DR†, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK, Ames C, McDermott MW, Barani IJ, Braunstein SE. Management of chordoma and chondrosarcoma with fractionated stereoetactic radiotherapy. Neurosurg Focus. 2017. 23;4:35. PMID: 28691010.
Kline CN, Packer RJ, Hwang EI, Raleigh DR, Braunstein S, Raffel C, Bandopadhayay P, Solomon DA, Aboian M, Cha S, Mueller S. Case-based review: pediatric medulloblastoma. Neurooncol Pract. 2017. 4:138-150. PMID: 29692919.
Raleigh DR, Choksi PK, Krup AL, Mayer W, Santos N, Reiter JR. Hedgehog signaling drives medulloblastoma growth via CDK6. J Clin Invest. 2017. 128:120-124. PMID: 29202464.
Wu A, Garcia MA, Magill ST, Chen W, Vasudevan HN, Perry A, Theodosopoulos PV, McDermott MW,Braunstein SE, Raleigh DR. Presenting symptoms and prognostic factors for symptomatic outcomes following resection of meningioma. World Neurosurg. 2017. 111:e149-e159. PMID: 29248774.